Citations

Mayo Clinic

Clear

496 citation(s) found for "H, K H Konstantinos".

Small duct primary sclerosing cholangitis without inflammatory bowel disease is genetically different from large duct disease
Næss, Sigrid, Anmarkrud, Jarl Andreas , Mamari, Said Al, Juran, Brian D., Chapman, Roger W. , Bergquist, Annika , Melum, Espen , Schrumpf, Erik, Lie, Benedicte A. , Boberg, Kirsten Muri , Karlsen, Tom H. , Hov, Johannes R. , Bjornsson, Einar Stefan , Lazaridis, Konstantinos N. , Marsh, Steven G. E. , Bergquist, Annika , Hov, Johannes R

Liver International | February 12, 2014 | Volume: 34 | Issue: 10 | Pages: 1488-1495

10.1111/liv.12492 | PMID 24517468 Get It

AbstractBackground & AimsSmall duct primary sclerosing cholangitis (PSC) is phenotypically a mild version of large duct PSC, but it is unknown whether these phenotypes share aetiology. We aimed to characterize their relationship by investigating genetic associations in the human leucocyte antigen (HLA) complex, which represent the strongest genetic risk factors in large duct PSC.MethodsFour classical HLA loci (HLA‐A, HLA‐B, HLA‐C and HLA‐DRB1) were genotyped in 87 small duct PSC patients, 485 large duct PSC patients and 1117 controls across three geographical regions.ResultsHLA‐DRB1*13:01 (OR = 2.0, 95% CI 1.2–3.4, P = 0.01) and HLA‐B*08 (OR = 1.6, 95% CI 1.1–2.4, P = 0.02) were significantly associated with small duct PSC compared with healthy controls. Based on the observed frequency of HLA‐B*08 in small duct PSC, the strongest risk factor in large duct PSC, an estimated 32% (95% CI 4–65%) of this population can be hypothesized to represent early stages or mild variants of large duct PSC. This subgroup may be constituted by small duct PSC patients with inflammatory bowel disease (IBD), which greatly resembled large duct PSC in its HLA association. In contrast, small duct PSC without IBD was only associated with HLA‐DRB1*13:01(P = 0.03) and was otherwise distinctly dissimilar from large duct PSC.ConclusionsSmall duct PSC with IBD resembles large duct PSC in its HLA association and may represent early stages or mild variants of large duct disease. Different HLA associations in small duct PSC without IBD could indicate that this subgroup is a different entity. HLA‐DRB1*13:01 may represent a specific risk factor for inflammatory bile duct disease.
The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome
Driscoll, James J. , Pelluru, Dheeraj, Lefkimmiatis, Konstantinos , Fulciniti, Mariateresa , Prabhala, Rao , Greipp, Philip R., Barlogie, Bart , Shaughnessy, John D. , Munshi, Nikhil C. , Tai, Yu‐Tzu , Anderson, Kenneth C. , Annunziata, Christina M.

Blood | November 30, 2009 | Volume: 115 | Issue: 14 | Pages: 2827-2834

10.1182/blood-2009-03-211045 | PMID 19965618 Get It

Abstract Multiple myeloma (MM) is a plasma cell neoplasm that proceeds through a premalignant state of monoclonal gammopathy of unknown significance; however, the molecular events responsible for myelomagenesis remain uncharacterized. To identify cellular pathways deregulated in MM, we addressed that sumoylation is homologous to ubiquitination and results in the attachment of the ubiquitin-like protein Sumo onto target proteins. Sumoylation was markedly enhanced in MM patient lysates compared with normal plasma cells and expression profiling indicated a relative induction of sumoylation pathway genes. The Sumo-conjugating enzyme Ube2I, the Sumo-ligase PIAS1, and the Sumo-inducer ARF were elevated in MM patient samples and cell lines. Survival correlated with expression because 80% of patients with low UBE2I and PIAS1 were living 6 years after transplantation, whereas only 45% of patients with high expression survived 6 years. UBE2I encodes the sole Sumo-conjugating enzyme in mammalian cells and cells transfected with a dominant-negative sumoylation-deficient UBE2I mutant exhibited decreased survival after radiation exposure, impaired adhesion to bone marrow stroma cell and decreased bone marrow stroma cell–induced proliferation. UBE2I confers cells with multiple advantages to promote tumorigenesis and predicts decreased survival when combined with PIAS1. The sumoylation pathway is a novel therapeutic target with implications for existing proteasomal-based treatment strategies.
NEAT-o-Games
Fujiki, Yuichi, Kazakos, Konstantinos, Puri, Colin, Buddharaju, Pradeep, Pavlidis, Ioannis , Levine, James A.

Computers in Entertainment | August 5, 2008 | Volume: 6 | Issue: 2 | Pages: 1-22

10.1145/1371216.1371224 Get It

This article describes research that aims to encourage physical activity through a novel pervasive gaming paradigm. Data from a wearable accelerometer are logged wirelessly to a cell phone and control the animation of an avatar that represents the player in a virtual race game with other players over the cellular network. Winners are declared every day and players with an excess of activity points can spend some to get hints in mental games of the suite, like Sudoku. The racing game runs in the background throughout the day and every little move counts. As the gaming platform is embedded in the daily routine of players, it may act as a strong behavioral modifier and increase everyday physical activity other than volitional sporting exercise. Such physical activity (e.g., taking the stairs), is termed NEAT and was shown to play a major role in obesity prevention and intervention. A pilot experiment demonstrates that players are engaged in NEAT-o-Games and become more physically active while having a good dosage of fun.
NEAT-o-games
Fujiki, Yuichi, Kazakos, Konstantinos, Puri, Colin, Pavlidis, Ioannis , Starren, Justin , Levine, James A.

CHI '07 Extended Abstracts on Human Factors in Computing Systems | June 6, 2007 | Volume: No volume available | Issue: No issue available | Pages: 2369-2374

10.1145/1240866.1241009 Get It

Liposomally targeted cytotoxic drugs for the treatment of cancer
Harrington, Kevin J. , Syrigos, Konstantinos N., Vile, Richard G. , Harrington, Kevin

Journal of Pharmacy and Pharmacology | January 24, 2003 | Volume: 54 | Issue: 12 | Pages: 1573-1600

10.1211/0022357002243 | PMID 12542887 Get It

The Development of Monoclonal Antibody Therapy in Leukemias
Syrigos, Konstantinos N., Pliarchopoulou, Kyriaki, Harrington, Kevin J.

Hybridoma | July 26, 2002 | Volume: 20 | Issue: 3 | Pages: 145-148

10.1089/027245701750293466 | PMID 11461662 Get It